Aglip - 12.5mg

Tablet

Pack Size : 10 Tablet x 1 strip

Generics : Alogliptin Benzoate

Manufacturer : Eskayef Pharmaceuticals Ltd.

Best Price * TK 120.00

* Delivery will be done in Dhaka city only.

Alternative Product

More Information About - Aglip - 12.5mg

Description

Generic Name

Alogliptin

Precaution

Patient with abnormal LFT, history of pancreatitis, moderate to severe heart failure. Hepatic and moderate to severe renal impairment. DPP-4 inhibitors may cause disabling joint arthralgia. Pregnancy and lactation.

Indication

Type 2 diabetes mellitus

Contra Indication

Type 1 diabetes mellitus or diabetic ketoacidosis. Hypersensitivity to alogliptin, including anaphylaxis, angioedema, or severe cutaneous adverse reactions including Stevens-Johnson syndrome

Dose

N/A

Side Effect

>10% Hypoglycemia (1.5-35%); higher when added to insulin 1-10% Nasopharyngitis (4.4%) Headache (4.2%) Upper respiratory tract infection (4.2%) <1% Hypersensitivity (0.6%) Pancreatitis (0.2%)

Pregnancy Category

Name : B

Description

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Mode of Action

Alogliptin inhibits dipeptidylpeptidase-4 (DPP-4), an enzyme that inactivates incretin hormones. Inhibition of DPP-4 result in an increase in the levels of hormones [e.g. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotrophic polypeptide)] which regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic ?-cells and decreasing glucagon secretion from the pancreatic ?-cells, leading to reduced hepatic glucose production.

Interaction

Increased risk of hypoglycaemia with sulfonylurea (e.g. metformin), thiazolidinedione (e.g. pioglitazone) and insulin.

Pregnancy Category Note

Pregnancy Category: B Lactation: Unknown whether distributed in breast milk

Adult Dose

Oral Type 2 diabetes mellitus Adult: 25 mg once daily. Hepatic impairment Mild-to-moderate (Child-Pugh A and B): No dosage adjustment required Severe (Child-Pugh C): Not studied

Child Dose

N/A

Renal Dose

Renal impairment Mild (CrCl >60mL/min): No dosage adjustment required Moderate (CrCl ?30 to <60 mL/min): Decrease dose to 12.5 mg PO qDay Severe (CrCl ?15 to <30 mL/min) or ESRD (CrCl <15 mL/min) or requiring hemodialysis: 6.25 mg PO qDay May administer without regard to the timing of dialysis Peritoneal dialysis: Not studied

Administration

May be taken with or without food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.